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Abstract Introduction: Cerebrospinal fluid (CSF) neurodegenerative markers are measured clinically to sup-
port a diagnosis of Alzheimer’s disease. Several preanalytical factors may alter the CSF concentra-
tions of amyloid b 1–42 (Ab1–42) in particular with the potential to influence diagnosis. We aimed to
determine whether routine handling of samples alters measured biomarker concentration compared
with that of prompt delivery to the laboratory.
Methods: Forty individuals with suspected neurodegenerative diseases underwent diagnostic lum-
bar punctures using a standardized technique. A sample of each patient’s CSF was sent to the labo-
ratory by four different delivery methods: (1) by courier at room temperature; (2) by courier, on ice;
(3) using standard hospital portering; and (4) after quarantining for.24 hours. Ab1–42, total tau (t-
tau), and phosphorylated tau (p-tau) levels measured using standard enzyme-linked immunosorbent
assay techniques were compared between transfer methods.
Results: There were no significant differences in Ab1–42, t-tau, or p-tau concentrations measured in
samples transported via the different delivery methods despite significant differences in time taken to
deliver samples.
Discussion: When CSF is collected in appropriate tubes, transferred at room temperature, and
processed within 24 hours, neurodegenerative markers can be reliably determined.
 2015TheAuthors. PublishedbyElsevier Inc. onbehalf of theAlzheimer’sAssociation.This is anopen
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Cerebrospinal fluid (CSF) measures of amyloid b 1–42
(Ab1–42), total tau (t-tau), and phosphorylated tau (p-tau)
can be used to help diagnose Alzheimer’s disease (AD)
pathology in individuals with cognitive impairment [1].
These measures are now incorporated into research
diagnostic criteria for AD [2,3] and as an inclusion
criterion and outcome measure for clinical trials of
disease-modifying drugs (www.clinicaltrials.gov/show/
NCT01760005). Measured Ab1–42, t-tau, and p-tau con-
centrations are known to be affected by a number of
potential confounding factors in preanalytical handling
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including vessel material and manufacturer [4], aliquot
storage volume [5] and number of transfers between ves-
sels [6], and thought to be affected by storage temperature
[7], with conflicting evidence about whether time from
lumbar puncture (LP) to CSF analysis reduces analyte
concentration [7,8]. This is a particular concern for
Ab1–42 which has a propensity to adsorb to the walls
of collection containers, as well as to aggregate with
itself and other proteins [8], thus reducing its measured
concentration. As CSF Ab1–42 is reduced in AD, such er-
rors can potentially result in individuals being erroneously
diagnosed as having AD pathology [5].
In many centers, CSF samples are transferred to the labo-
ratory on a nonurgent basis, often passing through the hands
of porters, specimen reception staff, and laboratory scientists
before being aliquoted, frozen, and processed. By contrast,
research samples are typically collected according to a stan-
dardized operating procedure which sees them rapidly deliv-
ered to the laboratory and frozen (see, for example http://
www.alzforum.org/sites/default/files/protocol_Biofluid_
Sample_Collection_Protocol_for_ADNI_0.pdf). This raises
questions about whether data from research studies are appli-
cable to “real-life” clinical cohorts.
The aim of this study was to determine whether the deliv-
ery method used to transport CSF from the bedside to the
laboratory for aliquoting and freezing, the transfer time,
and prompt cooling at the bedside alters the measured con-
centration of Ab1–42, t-tau, and p-tau.
2. Methods
2.1. Subjects
We recruited sequential individuals seen at the specialist
cognitive disorders clinics at the National Hospital for
Neurology and Neurosurgery, referred for diagnostic LP
for investigation of a suspected neurodegenerative condition.
At the time of clinical sampling, all individuals donated an
additional CSF sample for research, and basic demographic
data were recorded. The study was reviewed by the local
ethics committee (reference: 12/LO/1504), and all partici-
pants gave written consent. In those participants who lacked
capacity, proxy consent was obtained from a consultee.
2.2. Sample collection and randomization
Individuals who had an LP between the hours of 9 and
10.30 AM performed using a 22-gauge Quincke needle ac-
cording to locally agreed standard operating procedures.
No manometer was used. Four samples of 1-mL volume
were collected in polypropylene tubes (Sarstedt Product
code 63.9922.254) and numbered sequentially as either
0 (the first sample, discarded) or 1–3.
Three transport methods were used for each individual’s
samples with the order randomized using a random number
generator command in Stata: (1) samples were collected by a
designated laboratory technician within 10 minutes of
collection and transferred to the laboratory in a cool box con-
taining wet ice at 4C; (2) samples were collected by a desig-
nated laboratory technician who picked up the sample within
10 minutes of collection and transferred to the laboratory at
room temperature; and (3) samples were transferred to the
laboratory via the routine portering service. (4) A further
group of individuals (n5 10) had their third sample deliber-
ately “mistreated,” being quarantined at room temperature
for between 24 hours and 1 week. In the laboratory, samples
were centrifuged at 1750 relative centrifugal force for 5 mi-
nutes at room temperature and frozen at 280C within
15 minutes of arrival. Each sample was analyzed for Ab1–
42, t-tau, and p-tau using an INNOTEST enzyme-linked
immunosorbent assay (ELISA; copyright, Ghent, Belgium).
Laboratory staff were blinded to the transfer method.
2.3. Statistics
Sample size calculations were based on prior ELISA-
based measures of Ab1–42, t-tau, and p-tau from 456 indi-
viduals with suspected neurodegenerative disease, where
the mean (standard deviation) concentration (pg/mL) for
Ab1–42 5 520 (122), t-tau 5 556 (442), and p-tau 5 70.3
(37.2). Assuming a correlation between results from the
transfer methods of .0.9, 30 participants were needed to
detect a difference of 20% in sample concentration with
90% power and 5% risk of a type 1 error. Wilcoxon
matched-pairs signed-rank tests were used to compare the
level of each biomarker concentration between transport
methods, and reproducibility was compared between trans-
port methods using Pitman’s test of equality of variance
for paired samples. Spearman’s pairwise correlation coeffi-
cient was determined for differences in biomarker concen-
tration and delivery time. All analyses were conducted in
Stata version 12.1.
3. Results
Thirty subjects were included in the initial analysis
comparing transfer methods 1–3, including patients with
suspected Alzheimer and a range of non-Alzheimer pa-
thologies. Samples randomized to transport options 1
and 2 all arrived simultaneously in the laboratory within
30 minutes of collection. Samples randomized to transport
option 3 arrived a median of 24 minutes (range, 13–55)
later. There was no significant difference in measured
CSF Ab1–42, t-tau, and p-tau concentrations between
any of the transport methods, and no evidence that vari-
ance of CSF Ab1–42 or t-tau differed between the trans-
port methods. There was significant variance of p-tau
between transport methods 1 and 2 and between methods
1 and 3, this association being driven by a single data
point (Table 1, Fig. 1).
Measured t-tau concentration was weakly negatively
correlated with transport time for samples transported by
porter compared with those sent by courier at room
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temperature (Spearman’s r 20.42) and on wet ice (Spear-
man’s r 20.39). There was no correlation between Ab1–
42 or p-tau concentration and transport time.
For the 10 individuals who had samples sent by transport
method (1) and following quarantine (method 4), the latter
samples arrived at the laboratory 1440 minutes (range,
1440–4320) after collection (Table 2).
There was also no significant difference in measured CSF
Ab1–42, t-tau, and p-tau concentrations between transport
methods 1 and 4. There was a moderate negative correlation
Table 1
Measured CSF biomarker concentrations for each transport method, results of paired Wilcoxon signed-rank tests used to compare transport methods and
Pitman’s test for equality of variance
CSF
analyte
Transport
option 1*
Transport
option 2*
Transport
option 3*
Comparison of options 1
and 2
Comparison of options 1
and 3
Comparison of options
2 and 3
P different
level
P different
variance
P different
level
P different
variance
P different
level
P
different
variance
Ab1-42y 563 (436–775) 565 (448–696) 553 (450–691) .84 .24 .13 .88 .52 .42
T-tauy 486 (263–874) 455 (276–842) 546 (261–999) .15 .36 .59 .39 .73 .79
P-tauy 61 (42–96) 56 (43–97) 61 (43–105) .68 .74 .72 .04 .97 .03
Abbreviations: CSF, cerebrospinal fluid; Ab1–42, amyloid b 1–42; t-tau, total-tau; p-tau, phosphorylated tau.
NOTE. Option 1: Designated courier transported on wet ice; option 2: designated courier at room temperature; and option 3: standard hospital porter.
*pg/mL.
yMedian (interquartile range).
Fig. 1. Bland-Altman plots for measured CSF Ab1–42, t-tau, and p-tau concentrations comparing transport options 1 and 2, 1 and 3, and 2 and 3. Solid line
indicates mean difference between methods; dashed lines represent 95% reference range for difference between methods. Abbreviations: CSF, cerebrospinal
fluid; Ab1–42, amyloid b 1–42; t-tau, total-tau; p-tau, phosphorylated tau.
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between Ab1–42 concentration (Spearman’s r 20.52) and
weakly positive correlation with t-tau (0.43) and p-tau con-
centrations (0.37) and transport time, although these correla-
tions were not statistically significant.
4. Discussion
The clinical utility of CSF biomarkers for diagnosing AD
pathology in individuals with cognitive impairment and sus-
pected neurodegeneration is now well established in the
research setting [1] but it is less clear to what extent Ab1–
42, t-tau, and p-tau concentrations can be reliably measured
and interpreted in “real-life” clinical cohorts where samples
cannot always be collected according to gold-standard prac-
tices. This is to our knowledge the first prospective, random-
ized study to show that CSF samples collected in
polypropylene vessels can be transferred without cooling,
in a time frame and manner appropriate for routine clinical
practice, without significantly altering the measured concen-
tration of the most useful neurodegenerative markers, and
supports the findings of a prior smaller study suggesting
that biomarker concentrations may remain stable at room
temperature for up to 24 hours [8]. We found no consistent
or significant correlation between transfer time and
biomarker concentration for Ab1–42 or p-tau. P-tau was
negatively correlated with delivery time for delivery options
1–3 but this association was not observed for the quarantined
samples (option 4) when greater time differences were stud-
ied. Although not powered to study changes over this period,
this study suggests there may be no effect of transfer time on
Ab1–42, t-tau, or p-tau even when samples were quarantined
for up to a week.
The conclusions from this prospective, blinded, random-
ized study have significant implications for future use of
CSF as a clinical diagnostic tool. In many countries, use of
CSF sampling in the investigation of dementia is restricted
to specialist neurology centers. As biomarkers are increas-
ingly used as part of clinical diagnostic criteria and there
is a drive to identify AD in the earliest preclinical phase of
the illness, regional hospitals and memory centers are likely
to want to make use of CSF sampling to aid early diagnosis,
identify individuals for trials, and to improve the likelihood
of successful therapeutic intervention. These results show
that, provided samples are collected appropriately and in
suitable tubes and can reach a laboratory for aliquoting
and freezing within a reasonable time frame, robust results
can be obtained.
In recent years, there have been moves to improve harmo-
nization in CSF collection and handling methods between
centers to help standardize clinical cutpoints and facilitate
multicenter observational research studies and trials of dis-
ease modifying drugs, yet there is significant variation in
the time taken to transfer samples from bedside to laboratory
between centers for research biobanking [9]. These data
demonstrate that harmonization of this particular variable
may be less vital than other preanalytical factors such as
test-tube material and brand. A relative weakness of this
study is sample size. A significantly larger study could be
powered to detect smaller differences between transport
groups.
We recommend that clinical CSF is collected according
to a standardized operating procedure using polypropylene
collection tubes. Our data suggest that samples need not be
transferred to the laboratory on ice and that transfer times
of up to and beyond 24 hours may not alter the validity of
Ab1–42, t-tau, and p-tau measurement.
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Table 2
Measured CSF biomarker concentrations for transport options 1 and 4 (n5 10), results of pairedWilcoxon signed-rank tests used to compare transport methods
and Pitman’s test for equality of variance
CSF analyte Transport option 1* Transport option 4* Comparison of options 1 and 4
Transfer time (min) 30 (30–33.5) 1440 (1440–4320)
P different level P different level
Ab1-42y 563 (448–713) 565 (463–927) .20 .39
T-tauy 471 (273–874) 345.5 (252–538) .36 .50
P-tauy 60 (39–96) 50.5 (33–56) .26 .73
Abbreviations: CSF, cerebrospinal fluid; Ab1–42, amyloid b 1–42; t-tau, total-tau; p-tau, phosphorylated tau.
NOTE. Option 1: Designated courier transported on wet ice and option 4: Standard hospital porter, where samples were deliberately mistreated at room tem-
perature for .24 h.
*pg/mL.
yMedian (interquartile range).
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using PubMed. Although there are several pub-
lications about the importance of cerebrospinal
fluid (CSF) prehandling methods, there are none in
the clinical setting.
2. Interpretation: Our findings demonstrate that CSF
transport methods are not likely to have an effect as
significant as was previously thought on neurodegen-
erative biomarker concentration.
3. Future directions: CSF measurement of neuronal-
enriched proteins is feasible outside the context of
the research environment.
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